CA
CYTO

Cortland Advisers’s Altamira Therapeutics Ltd CYTO Stock Holding History

Cortland Advisers’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-20
Closed -$7.73M – 47
2015
Q2 		$7.73M Buy
+20
New +$8.29M 0.13% 52

Other funds holding CYTO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BAMS
Bellevue Asset Management (Switzerland) Kuesnacht, Switzerland $656M AUM 11.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $486M AUM 34.86% 1-Year Est. Return

Cortland Advisers's CYTO Position: Q3 2015 in Review

Cortland Advisers sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2015, closing a stake of 20 shares — an estimated $7.73M sold.

Cortland Advisers first reported a position in CYTO in Q2 2015 and held it in 1 quarter. The position peaked at $7.73M in Q2 2015. 10 funds tracked by Wall St. Rank hold CYTO as of Q3 2015.

  • Cortland Advisers reported no remaining Altamira Therapeutics Ltd position as of Q3 2015 after selling out during the quarter.
  • Cortland Advisers sold 20 Altamira Therapeutics Ltd shares in Q3 2015, an estimated $7.73M.
  • Cortland Advisers first reported a position in Altamira Therapeutics Ltd in Q2 2015 and held it in 1 quarter.
  • Cortland Advisers's Altamira Therapeutics Ltd position peaked at $7.73M in Q2 2015.
  • 10 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2015.

Based on Cortland Advisers's 13F filing for Q3 2015, filed 12 Nov 2015.